IGC Pharma, Inc. has activated a new clinical trial site at Tandem Clinical Research in Metairie, Louisiana, for its Phase 2 CALMA study evaluating IGC‑AD1 in patients with agitation associated with Alzheimer’s disease. The site, located at 3901 Houma Boulevard, is expected to increase enrollment capacity and accelerate data collection, potentially shortening the time to readout for the trial’s primary endpoints.
CEO Ram Mukunda said, "With enrollment now over 70% complete, expanding to this highly qualified investigational site with strong neurological expertise strengthens the trial's geographic reach, and enhances patient access. We look forward to working closely with Dr. Traylor and her team." The statement underscores the company’s focus on broadening geographic reach and improving recruitment efficiency.
The expansion comes as IGC Pharma faces a limited cash runway and a tight deadline to deliver positive Phase 2 results before the end of 2026. In a highly competitive therapeutic area, the company’s cannabinoid‑based therapy and AI‑driven trial optimization are key differentiators, but the need for timely data remains a critical risk factor.
By adding the Louisiana site, IGC Pharma aims to meet enrollment targets more quickly, a move that could shorten the overall trial timeline and bring the company closer to regulatory submission and eventual market entry for IGC‑AD1.
The company has recently completed a registered direct offering in January 2026 to fund its clinical development, and it continues to navigate regulatory uncertainties surrounding cannabis‑derived products. The new site activation is part of a broader strategy to strengthen the trial’s execution and mitigate recruitment headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.